ADARx Pharmaceuticals, Inc. (ADRX) Stock
NYSE · ADRX
19.35
Fundamentals
Market cap
$1.98B
Price / Earnings ratio
199.5x
Price / Sales ratio
N/A
Price / Book ratio
2.4x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Reuters
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
NeutralADRXSeptember 25, 2026
ReutersNeutral
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

Reuters
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
NeutralADRXSeptember 21, 2026
ReutersNeutral
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
Technicals
Not enough data
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Reuters
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
NeutralADRXSeptember 25, 2026
ReutersNeutral
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

Reuters
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
NeutralADRXSeptember 21, 2026
ReutersNeutral
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs.
Fundamentals
Valuation
Market cap$1.98B
Price-to-sales ratioN/A
Price-to-book value2.39
Price-earnings ratio199.50
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$0.13
Income Statement
Average volumeN/A
EBITDAN/A
1 year high (52w)N/A
1 year low (52w)N/A
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
Not enough data
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 |



